Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

COVID-19

Neutralization susceptibility of Omicron lineages

Two studies in Nature and Cell look at the ability of vaccine-induced and infection-induced sera to neutralize the newer BA.2.12.1, BA.4 and BA.5 sublineages of SARS-CoV-2 Omicron compared with BA.1 and BA.2. Tuekprakhon et al. and Cao et al. show that serum from triple-vaccinated individuals (Pfizer, AstraZeneca or CoronaVac), and from vaccinated individuals who experienced a breakthrough infection with BA.1, has reduced ability to neutralize BA.4/5 and BA.2.12.1 compared with BA.1/2 as a result of L452R and F486V (BA.4/5) and L452Q (BA.2.12.1) mutations in the receptor binding domain (RBD). Similar results were reported for most commercially available monoclonal antibodies in terms of further reduced neutralization activity against the newer Omicron sublineages. Tuekprakhon et al. also report that the RBD of BA.4/5 has higher affinity for the host receptor ACE2 than BA.1/2, whereas Cao et al. find that the ACE2-binding affinities are similar.

References

Original article

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kirsty Minton.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Minton, K. Neutralization susceptibility of Omicron lineages. Nat Rev Immunol 22, 463 (2022). https://doi.org/10.1038/s41577-022-00756-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41577-022-00756-7

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing